HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. Journal Of The National Cancer Institute 2019, 112: 46-54. PMID: 31037288, PMCID: PMC7850037, DOI: 10.1093/jnci/djz042.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicFemaleGene ExpressionHumansLapatinibMiddle AgedMolecular Targeted TherapyNeoadjuvant TherapyNeoplasm StagingPrognosisReceptor, ErbB-2Reproducibility of ResultsSurvival AnalysisTreatment OutcomeConceptsHER2-positive breast cancerProgression-free survivalOverall response rateHER2-positive diseasePathological complete responseOverall survivalBreast cancerEarly diseaseAdvanced HER2-positive diseaseLonger progression-free survivalHigher overall response rateDual HER2 blockadeLonger overall survivalHER2-positive tumorsHER2 blockadeNeoadjuvant lapatinibNeoadjuvant trastuzumabAdvanced diseaseComplete responsePrimary outcomeClinical trialsIntrinsic subtypesIdentifies tumorsAdvanced settingERBB2 mRNA